A recovery claim needs more than a menu
BPC-157 and TB-500 appear in current peptide marketing, including Defy Medical’s service description. A clinic naming a compound documents an advertised service, not the outcome a patient can expect. We have not added a consumer purchase price for either ingredient because this edition does not establish a sufficiently specified current product and clinical price.
Sources: Defy Medical — peptide therapy, FDA — compounding substances with potential safety risks, FDA — July 2026 compounding advisory meeting
Keep the compound’s identity exact
FDA’s safety page identifies the thymosin beta-4 fragment LKKTETQ under the name TB-500. That specificity matters: evidence about a differently named full-length peptide cannot simply be assigned to every product using a short commercial label. A blend adds another identity question because its amount of each ingredient must be known before a price-per-milligram calculation means anything.
Sources: Defy Medical — peptide therapy, FDA — compounding substances with potential safety risks, FDA — July 2026 compounding advisory meeting
What the FDA risk information says
FDA describes potential immune-response and peptide-impurity concerns for these compounds and gaps in relevant human safety information. This is a reason to preserve uncertainty, not a basis for claiming a known risk percentage. The agency’s page also distinguishes substances in interim categories from nominations that were withdrawn; a single sweeping banned-or-approved label would erase those differences.
Sources: Defy Medical — peptide therapy, FDA — compounding substances with potential safety risks, FDA — July 2026 compounding advisory meeting
Committee discussion is not a product approval
BPC-157 and TB-500 appeared on the July 2026 compounding advisory meeting agenda. A meeting entry alone does not establish the committee’s final action, a binding rule or approval of a particular preparation. Check the exact regulatory record and the actual product. A research-only bottle, provider treatment page and approved medicine should never share a price ranking that implies equivalent clinical status.
Sources: Defy Medical — peptide therapy, FDA — compounding substances with potential safety risks, FDA — July 2026 compounding advisory meeting
Keep reading.
Follow the evidence
Sources & price notes
Each source retains its own check date. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- Defy Medical — peptide therapy ↗
Provider service description and care process. No current itemized medicine price was established; older downloadable pricing sheets were excluded.
Checked October 9, 2026
- FDA — compounding substances with potential safety risks ↗
Includes injectable GHK-Cu; route-specific concerns must not be applied indiscriminately to cosmetics. Regulatory page rechecked October 9, 2026; retain distinctions between approval, risk information and compounding nominations.
Checked October 9, 2026
- FDA — July 2026 compounding advisory meeting ↗
Meeting topics include several nominated peptides. Committee discussion does not itself grant drug approval or establish current dispensing eligibility.
Checked October 9, 2026